Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients

[1]  W. Winkelmayer,et al.  Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients , 2023, Kidney medicine.

[2]  Kimberly A. Walters,et al.  Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. , 2021, The New England journal of medicine.

[3]  D. Tarng,et al.  Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Conference. , 2021, Kidney international.

[4]  Z. Massy,et al.  A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps , 2021, Scientific Reports.

[5]  A. Covic,et al.  Health-related quality of life in patients with chronic kidney disease , 2020, Expert review of pharmacoeconomics & outcomes research.

[6]  Kimberly A. Walters,et al.  Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD:  Design and Baseline Characteristics. , 2020, American heart journal.

[7]  C. Jacquelinet,et al.  Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated , 2019, Clinical kidney journal.

[8]  Neil R. Powe,et al.  Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy , 2017, The Lancet.

[9]  S. Yusuf,et al.  Interpreting Geographic Variations in Results of Randomized, Controlled Trials. , 2016, The New England journal of medicine.

[10]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[11]  D. Gilbertson,et al.  Red blood cell transfusion use in patients with chronic kidney disease. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Wim Van Biesen,et al.  Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  C. O'connor,et al.  Implications of geographical variation on clinical outcomes of cardiovascular trials. , 2012, American heart journal.

[14]  Chapter 3: Use of ESAs and other agents* to treat anemia in CKD , 2012, Kidney international. Supplement.

[15]  C. Held,et al.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. , 2011, Circulation.

[16]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[17]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[18]  B. Gersh.  Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2012 .

[19]  J. Adamson,et al.  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .